In vitro evaluation of the effectiveness and cytotoxicity of meglumine antimoniate microspheres produced by spray drying against Leishmania infantum

Parasitology Research

Volumn 102, Issue 6, 2008, Pages 1243-1247

  Pujals, G ^a   Sune Negre J M ^a   Perez P ^a   Garcia E ^a   Portus, M ^a   Tico, J R ^a   Minarro M ^a   Carrio J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; CHITOSAN; FEMALE; INHIBITORY CONCENTRATION 50; LEISHMANIA INFANTUM; MACROPHAGES, PERITONEAL; MEGLUMINE; MICE; MICROSPHERES; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS;

LEISHMANIA INFANTUM;

EID: 42049109499     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-008-0901-z     Document Type: Article

References (22)

1. Basu MK, Lala S (2004) Macrophage specific drug delivery in experimental leishmaniosis. Curr Mol Med 4(6):681-689
2. Carrió J, de Colmenares M, Riera C, Gállego M, Arboix M, Portús M (2000) Leishmania infantum: stage-specific activity of pentavalent antimony related with the assay conditions. Exp Parasitol 95:209-214
3. Chirkov SN (2002) The antiviral activity of chitosan. Appl Biochem Microbiol 38(1):5-13, Translated from Prikladnaya Biokhimiya i Mikrobiologiya
4. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G (2004) Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 278:119-131
5. Demicheli C, Ochoa R, Da Silva JBB, Falçao CAB, Rossi-Bergmann B, De Melo AL, Sinisterra RD, Frézard F (2004) Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniosis. Antimicrob Agents Chemother 48(1):100-103
6. Faraut-Gambarelli F, Piarroux R, Deniau M, Giusiano B, Marty P, Michel G, Fauge're B, Dumon H (1997) In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniosis. Antimicrob Agents Chemother 41(4):827-830
7. Felt O, Carrel A, Baehni P, Buri P, Gurny R (2000) Chitosan as tear substitute: a wetting agent endowed with antimicrobial efficacy. J Ocul Pharmacol Ther 16:261-270
8. Frézard F, Michalick MSM, Soares CF, Demicheli C (2000) Novel methods for the encapsulation meglumine antimoniate into liposomes. Braz J Med Biol Res 33:841-846
9. Guerin J, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Brycesoniero ADM (2002) Visceral leishmaniosis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet 2:494-501
10. Guo Z, Chen R, Xing R, Liu S, Yu H, Wang P, Li C, Lia P (2006) Novel derivatives of chitosan and their antifungal activities in vitro. Carbohydr Res 341:351-354
11. Hejazi R, Amiji M (2003) Chitosan-based gastrointestinal delivery systems. J Control Release 89:151-165
12. Jumaa M, Furkert FH, Müller BW (2002) A new lipid emulsion formulation with high antimicrobial efficacy using chitosan. Eur J Pharm Biopharm 53:115-123
13. Kim J, Lee HC, Oh JS, Shin BA, Oh CS, Park RD, Yang KS, Cho CS (1999) Polyelectrolyte complex composed of chitosan and sodium alginate for wound dressing application. J Biomater Sci Polym Ed 10:543-556
14. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D (1999) Evidence that the high incidence of treatment failures in Indian Kala-Azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180:564-567
15. Ouellette M, Hettema E, Wüst D, Fase-Fowler F, Borst P (1991) Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania. EMBO J 10:1009-1016
16. Perez-Victoria JM, Di Pietro A, Barron D, Ravelo AG, Castanys S, Gamarro F (2002) Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents. Curr Drug Targets 3(4):311-333
17. Porporatto C, Bianco ID, Riera CM, Correa SG (2003) Chitosan induces different l-arginine metabolic pathways in resting and inflammatory macrophages. Biochem Biophys Res Commun 304:266-272
18. Prego C, García M, Torres D, Alonso MJ (2005) Transmucosal macromolecular drug delivery. J Control Release 101:151-162
19. Schettini DA, Costa Val AP, Souza LF, Demicheli C, Rocha OGF, Melo MN, Michalick MSM Frézard F (2003) Distribution of liposome-encapsulated antimony in dogs. Braz J Med Biol Res 36:269-272
20. Schipper NGM, Varum KM, Artusson P (1996) Chitosan as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (caco-2) cells. Pharm Res 13(11):1686-1692
21. Tempone AG, Perez D, Rath S, Vilarinho AL, Mortara RA, de Andrade JHF (2004) Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 54:60-68
22. Valiathan R, Dubey ML, Mahajan RC, Malla N (2006) Leishmania donovani: effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Indian clinical isolates to sodium stibogluconate. Exp Parasitol 114(2):103-108